Opendata, web and dolomites

REAP SIGNED

Repair of DNA lesions induced by platinum drugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 REAP project word cloud

Explore the words cloud of the REAP project. It provides you a very rough idea of what is the project "REAP" about.

benefit    insensitive    genes    treat    validation    repair    backgrounds    bulky    striking    knockout    nucleotide    tissues    union    characterization    pilot    vital    inducing    experts    mutated    outcomes    excision    sensitive    potentially    ner    follows    recognition    resistance    molecular    scientific    oxaliplatin    gg    differential    half    unreported    dna    cas9    receiving    schemes    treatment    platinum    cancer    host    shown    genome    chemotherapy    observations    damage    identification    multidisciplinary    multiple    difference    tumors    translational    validated    understand    crispr    performing    experimental    functional    nonmalignant    regulate    transfer    unrecognized    commitment    data    expressed    unbiased    cisplatin    patient    versus    ambition    followed    novelty    considerable    global    extrapolate    lesions    efficient    patients    principles    cells    tumor    drugs    deficient    genetic    ddr    cytotoxicity    techniques    unable    screens    differently   

Project "REAP" data sheet

The following table provides information about the project.

Coordinator
CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH 

Organization address
address: LAZARETTGASSE 14 AKH BT 25.3
city: WIEN
postcode: 1090
website: http://www.oeaw.ac.at/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 186˙167 €
 EC max contribution 186˙167 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH AT (WIEN) coordinator 186˙167.00

Map

 Project objective

DNA damage-inducing platinum drugs, such as oxaliplatin and cisplatin, are used to treat about half of all patients receiving chemotherapy. Although potentially very efficient, many patients develop resistance for yet unrecognized reasons. Better understanding of the DNA damage response (DDR) to platinum-DNA lesions is therefore much needed for improving treatment outcomes. By performing DDR-dedicated CRISPR/Cas9 knockout screens, the applicant has shown that some cancer cells deficient in the major repair of bulky DNA lesions, global-genome nucleotide excision repair (GG-NER), are insensitive to oxaliplatin but sensitive to cisplatin. This striking difference remains as of yet unreported, but might explain differential responses of tumors to drugs. The aim of this proposal is to understand why GG-NER is unable to repair oxaliplatin lesions in particular genetic backgrounds. To do so, unbiased identification of genes differently mutated or expressed in oxaliplatin-sensitive versus insensitive cells will be followed by validation and in-depth functional characterization of identified targets. The ambition is to extrapolate experimental observations to translational knowledge. Validated targets will be studied in patient-derived tumor tissues as compared to nonmalignant tissues and related to patients’ treatment responses. Identification of genetic factors that regulate platinum lesions recognition by GG-NER will contribute to the understanding of molecular principles of platinum drugs cytotoxicity and might thus have considerable benefit on current cancer treatment schemes. The novelty of the pilot data, the unique multidisciplinary design of the project, the use of state-of-the-art molecular techniques and a collaboration with multiple European experts will ensure high scientific impact. Both, the applicant and the host will greatly benefit from the vital knowledge transfer. This project follows the European Union's commitment to cancer research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PNAIC (2018)

Positive and Negative Asymmetry in Intergroup Contact: Its Impact on Linguistic Forms of Communication and Physiological Responses

Read More  

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More  

UMMs (2019)

Unifying Monitoring Models of Verbal Monitoring.

Read More